Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medarex deal

Merck would provide between $2.75-$4 million in the first year in R&D funding, with up to $25 million in additional funding contingent on the achievement of

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE